The study is a 12‑week trial designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of the candidate XEN‑D0501, which the Malmö‑based company is developing as a potential treatment for obesity and type 2 diabetes.
XEN‑D0501 is an oral TRPV1 antagonist that blocks a pain and heat receptor – often referred to as the “chili receptor” – which also plays a role in metabolism, inflammation and insulin regulation, as previously reported.
BREAKING